Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 13 Sep 2019 Planned primary completion date changed from 31 Aug 2019 to 28 Feb 2020.
- 18 Jan 2018 Planned primary completion date changed from 15 Jan 2018 to 31 Aug 2019.
- 20 Jan 2017 Status changed from recruiting to active, no longer recruiting.